In a recent filing with the Securities and Exchange Commission, Tenaya Therapeutics, Inc. disclosed the upcoming departure of Leone Patterson, the company's Chief Financial and Business Officer (CFBO). The notice, dated July 19, 2024, stated that Patterson will leave her position to pursue another opportunity.
Patterson, who also serves as the Principal Financial (NASDAQ:PFG) Officer and Principal Accounting Officer for the South San Francisco-based biotechnology firm, will continue her duties until August 14, 2024, to support a smooth transition of her responsibilities. Tenaya confirmed that Patterson's resignation did not stem from any disagreements regarding the company's financial statements, operations, policies, or practices.
Tenaya Therapeutics, which specializes in biological products, is now actively seeking a new Chief Financial Officer. The company, listed on the Nasdaq Global Select Market under the ticker NASDAQ:TNYA, has not yet named a successor.
In other recent news, Tenaya Therapeutics has reported significant changes in its board and research leadership team. Board member Jin-Long Chen resigned, and Kathy Ivey, Ph.D., was promoted to Senior Vice President, Research, while Timothy Hoey, Ph.D., transitioned to an advisory role. Additionally, Barry J. Byrne, M.D., Ph.D., joined the Scientific Advisory Board.
In analyst news, William Blair initiated coverage of Tenaya Therapeutics with an Outperform rating, highlighting a positive outlook for the company's gene therapy candidates, TN-201 and TN-401. Concurrently, Canaccord Genuity maintained a Buy rating on Tenaya but lowered the price target to $16.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.